Abstract

BackgroundUnderstanding potential risk factors and phenotypes at-risk of anaphylaxis can tailor public health actions to prevent avoidable deaths. Therefore, our aim was to explore patterns of hospital admissions diagnosed with anaphylaxis in France from 2012 to 2021, across different age groups, using the national French hospital database and to evaluate potential determinants to propose phenotypes at-risk, with a particular view to severe cases. MethodsThis is a descriptive study, using data from the French Program for the Medicalization of Information Systems, from 2012 to 2021. We included all patients hospitalized for anaphylaxis using International Classification of Diseases (ICD)-10 codes listed as a primary diagnosis. Potential risk factors were selected according to corresponding ICD codes, available as secondary data of hospitalization. Severe anaphylaxis (SA) was defined based on the need of admissions in intensive care units. To explore the patterns and characteristics, we employed cluster analysis using the clustering large applications algorithm. Charlson comorbidity index (CCI) was used to evaluate comorbidities. ResultsDuring the 9-year study period, 78,453 patients had 86,654 admissions due to anaphylaxis for all-causes. Most of the cases were non-severe anaphylaxis (93.7%), 5.9% were SA, and 0.4% evolved to fatal anaphylaxis (FA). Rate of admissions for SA was 0.08/100,000/year. Seasonal trend of cases of anaphylaxis due to Hymenoptera venoms were shown. Increased severity and risk of death were significantly higher in the elderly. Food-induced anaphylaxis is more frequent in childhood, but SA occurred at adolescence and early adulthood. The CCI was higher in SA and FA. By applying the clustering algorithm CLARA, we identified 3 clusters distributed according to the severity. ConclusionMore than providing a snap shot of potential risk factors for anaphylaxis in France, we were able to suggest phenotypes of anaphylaxis of different severities and to propose actions based on our findings. Although further research is needed in the field, we strongly believe that the data presented may contribute to public health advancements to ensure quality of care of patients suffering from anaphylaxis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.